Swedish Orphan Biovitrum investor relations material
Listen to the latest call from Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. The company operates through three segments: Haemophilia & Hereditary Diseases, Inflammation & Immunology, and Other. It offers Alprolix for hemophilia B; Elocta to treat hemophilia A; Doptelet for thrombocytopenia; Kineret for rheumatoid arthritis; Thiola for cystinuria; Xultophy Cartridge that is used with Flexpen for treatment of diabetes; and Velphoro for hyperphosphatemia.